The Trump administration has finalized a rule that will prevent federal Medicaid and Children’s Health Insurance Program (CHIP) funds from being used for certain gender-transition medical treatments for children and adolescents.
Eko Hot News reports that the policy will affect federal funding for treatments including puberty blockers, hormone therapy and surgical procedures for eligible young people covered by the programmes.
The new rule is part of the administration’s broader healthcare policy concerning medical care for minors experiencing gender dysphoria.
Under the policy, federal Medicaid funding will no longer cover the specified treatments for patients under 18.
For CHIP, the restriction applies to beneficiaries under 19.
The policy is scheduled to take effect in October 2026, according to reports on the finalized rule.
Medicaid and CHIP provide health coverage to millions of children and families across the United States.
The administration said its decision is aimed at protecting children and ensuring that federal healthcare funds are used for treatments it considers appropriately supported.
Officials have argued that there are continuing questions about the evidence and long-term effects associated with some transition-related treatments for minors.
The policy does not prohibit such medical care nationwide.
Instead, it limits the use of federal Medicaid and CHIP funding for the specified treatments.
States may still have different options concerning the use of their own funds, depending on applicable state laws and healthcare policies.
The change could therefore produce different effects across the United States.
States that currently provide coverage for these treatments may need to consider how they will respond once federal funding restrictions take effect.
The administration’s decision follows earlier efforts by President Donald Trump to change federal policy concerning gender-related healthcare for minors.
Trump issued an executive order in January 2025 directing federal agencies to take steps aimed at ending federal support for specified transition-related procedures involving children.
The latest rule represents a further step in implementing that policy direction through Medicaid and CHIP.
The administration has maintained that federal taxpayers should not be required to finance treatments it considers unsuitable for minors.
Officials also said the policy is intended to protect children and ensure responsible use of public healthcare resources.
The decision has attracted strong criticism from medical organisations and healthcare advocates.
Opponents argue that the federal government is interfering with medical decisions involving young people, their families and healthcare professionals.
Some medical groups have also questioned the administration’s interpretation of existing healthcare law.
Public health organisations previously argued that the federal government lacked sufficient authority to impose the proposed restrictions on Medicaid and CHIP funding.
The policy is therefore expected to generate further legal and political debate.
Legal challenges could determine whether the rule remains in effect as scheduled.
The final rule also provides a transition period for some patients already receiving certain treatments.
Reports indicate that federal funding for existing hormone therapy may continue for a limited period before the restrictions are fully implemented.
Mental health services related to gender dysphoria will remain covered under the policy, according to reports.
The administration’s action focuses primarily on medical interventions associated with gender transition.
The policy also distinguishes between Medicaid and CHIP based on the age of beneficiaries covered by each programme.
The financial effect of the decision is expected to be relatively small compared with overall Medicaid and CHIP expenditure.
However, the impact could be significant for families who rely on public health coverage for the treatments affected by the new policy.
Healthcare providers may also need to review how they handle patients covered through federal programmes.
States will have to assess the implications for their Medicaid and CHIP systems.
The issue could become particularly important in states that have previously maintained coverage for gender-affirming care.
The federal government’s position is that states should not use federal funds for the treatments covered by the new restriction.
At the same time, states retain authority over many aspects of their own healthcare programmes, subject to federal requirements.
This could result in differences in coverage from one state to another.
The new rule is also likely to influence the wider debate over healthcare policy for transgender young people in the United States.
Supporters of the policy say it strengthens safeguards for minors.
Critics say it could make healthcare less accessible for young people who depend on Medicaid or CHIP.
The debate has already produced different policies across states.
Some states have introduced restrictions on transition-related healthcare for minors, while others have maintained access under their state laws.
The federal rule adds another layer to that complex policy environment.
For families affected by the change, the availability of treatment and funding could depend increasingly on state policy and other sources of health coverage.
The administration has defended the rule as part of its commitment to its healthcare and child-protection agenda.
Officials said federal resources should support medical services that meet the administration’s standards for evidence and benefit.
Critics, meanwhile, maintain that decisions about individual medical care should be made by patients, families and qualified healthcare professionals.
The disagreement is expected to continue through political and legal channels.
The implementation date will be closely watched by states, healthcare providers and affected families.
Further court proceedings could also influence when or whether the policy is fully implemented.
The Trump administration has continued to make changes to federal policies concerning transgender healthcare.
The Medicaid and CHIP rule represents one of the most significant financial changes affecting access to transition-related medical care for young people.
As the implementation date approaches, states are expected to review their programmes and determine how to respond.
Healthcare organisations will also monitor developments surrounding the rule and any legal challenges.
For now, the federal government is moving ahead with its plan to restrict Medicaid and CHIP funding for specified transition-related medical treatments involving minors.
The policy marks another major shift in U.S. federal healthcare policy under President Trump.
